This article was originally published in The Rose Sheet
Executive SummaryFragrance division revenues advanced 3.3% in local currencies, or 2.8% in Swiss francs, to $664.3 mil. (CHF1=$.78) for the nine month period, flavors and fragrances company announces. Despite a number of new launches, particularly in North America, fine fragrances business continued to perform below last year's level, firm notes. Consumer products sales within the fragrance division outperformed the market, with double-digit growth in North America, although fragrance ingredient sales were below the prior year level. Givaudan net sales during the period were up 1.6% in local currencies, or 1% in Swiss francs, to $1.63 bil., firm adds...
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."